Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial Monday December 4, 7:00 am ET - New drug application planned for mid-2007 - PALO ALTO, Calif. and DEERFIELD, Ill., Dec. 4 -- CV ...

The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital ...

Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...

Already used in Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) for adult patients, Rapiscan is now approved for use in stress Cardiac Magnetic Resonance Imaging ...

Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Hikma is offering Regadenoson ...

CV Therapeutics Inc.'s regadenoson to boost coronary blood flow for better myocardial perfusion imaging hit the primary endpoint in the first of two pivotal Phase III studies, and the company is ...

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent ...